Endosonics buys Dutch micromotor developer

Article

Du-Med's tiny technology to be used in catheter lineEndosonics this month announced that it has purchased Du-Med,a micromotor technology developer based in the Netherlands. Theacquisition follows a strategic alliance formed last year betweenthe

Du-Med's tiny technology to be used in catheter line

Endosonics this month announced that it has purchased Du-Med,a micromotor technology developer based in the Netherlands. Theacquisition follows a strategic alliance formed last year betweenthe companies to integrate Du-Med's miniaturized micromotors intoEndosonics' medical catheters.

Du-Med was formed six years ago to commercialize miniaturizedmicromotor technology developed at Erasmus University in Rotterdam.The motors, which are less than 1 mm in size, can be placed onthe end of catheters to produce ultrasound signals.

To acquire Du-Med, Pleasanton, CA-based Endosonics agreed toissue 560,000 shares of Endosonics restricted common stock toDu-Med investors in a deal worth up to $3.5 million. Du-Med investorswill receive additional payments contingent on future revenuesof products sold using Du-Med technology.

Endosonics and Du-Med formed a strategic alliance to developand distribute Du-Med's micromotor imaging products in October1993. Endosonics is integrating Du-Med's technology into a lineof catheter imaging products, which the company expects to beginmarketing for non-cardiovascular applications next year.

In other news, Endosonics last month announced its sales andrevenue figures for the second quarter (end-June). Strong salesof its Oracle Imaging System to European and Japanese customershelped Endosonics record a 47% increase in revenues for the secondquarter. Despite the increase, Endosonics recorded a loss forthe quarter.

Endosonics revenues for the quarter totaled $1.2 million, asharp increase over the $822,000 in the same period last year.The firm posted a net loss of $3.2 million compared to a lossof $4.7 million in the second quarter of 1993.

International sales of Oracle are the primary reason for therevenue growth, according to the company. In addition, Endosonicsrecently introduced two drug delivery catheters, Transport andBullett.

Endosonics also said that it is complying with a Food and DrugAdministration request to revise the data in its application forits Oracle-Micro coronary balloon angioplasty-imaging catheter.An FDA panel reviewing the application told the company that theapplication was not approvable until the data were revised. Endosonicsshould complete its revision in about a month, according to thecompany.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.